Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2011. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons under the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share plan notifications.
- Share Price (Ordinary Shares): £12.50
- Share Price (ADRs): $39.05
- Dividend Payment Date: January 6, 2011
Material Changes
On January 12, 2011, the Administrators of the GlaxoSmithKline Performance Share Plan notified the Company of an increase in notional interests for various directors and managers. This increase resulted from the notional re-investment of the dividend paid on January 6, 2011.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance notification regarding the vesting mechanics of the Performance Share Plan, where accrued notional dividends will be paid out based on the percentage of holdings that vest after the relevant three-year measurement period.
Investor Verification Checklist
- Verify the specific number of notional shares allocated to each named director in the Performance Share Plan.
- Confirm the vesting schedule and conditions for the three-year measurement period referenced in the plan.
- Review the company's broader financial results for the period ending January 2011 in other filings (e.g., Form 20-F or press releases) as this document does not contain financial performance data.